The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer

Cancer Research

Volumn 65, Issue 19, 2005, Pages 8818-8825

  Miwa, Sotaro ^a   Mizokami, Atsushi ^a   Keller, Evan T ^b   Taichman, Russell ^c   Zhang, Jian ^b   Namiki, Mikio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; MINODRONIC ACID; STROMAL CELL DERIVED FACTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE CANCER; BONE DEVELOPMENT; BONE MATRIX; BONE METASTASIS; CANCER CELL CULTURE; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TIBIA;

ANIMALS; BONE MARROW; BONE NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHEMOKINES, CXC; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; MICE; MICE, SCID; NEOPLASM INVASIVENESS; OSTEOBLASTS; PROSTATIC NEOPLASMS; RECEPTORS, CXCR4; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 25444529945     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0540     Document Type: Article

References (49)

1. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma: analysis of 1000 autopsied cases. Cancer 1950;3:74-85.
2. Koutsilieris M. Osteoblastic metastasis in advanced prostate cancer. Anticancer Res 1993;13:443-9.
3. Roland SI. Calcium studies in ten cases of osteoblastic prostatic metastasis. J Urol 1958;79-339-42.
4. Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000;82:858-64.
5. Sano M, Kushida K, Takahashi M, et al. Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis. Br J Cancer 1994;70:701-3.
6. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol 1991;9:509-24.
7. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961-78.
8. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-54.
9. Green JR. Antitumor effects of bisphosphonates. Cancer 2003;97:840-7.
10. Green JR Anti-tumor potential of bisphosphonates. Med Klin (Munich) 2000;95:23-8.
11. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002;62:1832-7.
12. Darash-Yahana M, Pikarsky E, Abramovitch R, et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 2004;18:1240-2.
13. Sun YX, Wang J, Shelburne CE, et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003;89:462-73.
14. Singh S, Singh UP, Grizzle WE, Lillard JW, Jr. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest 2004;84:1666-76.
15. Vaday GG, Hua SB, Peehl DM, et al. CXCR4 and CXCL12 (SDF-1) in prostate cancer: inhibitory effects of human single chain Fv antibodies. Clin Cancer Res 2004;10:5630-9.
16. Sun YX, Schneider A, Jung Y, et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 2005;20:318-29.
17. Burger M, Glodek A, Hartmann T, et al. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogens 2003;22:8093-101.
18. Fernandis AZ, Prasad A, Band H, Klosel R, Ganju RK. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 2004;23:157-67.
19. Bartolome RA, Galvez BG, Longo N, et al. Stromal cell-derived factor-1α promotes melanoma cell invasion across basement membranes involving stimulation of membrane-type 1 matrix metalloproteinase and Rho GTPase activities. Cancer Res 2004;64:2534-43.
20. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235-44.
21. Corey E, Quinn JE, Bladou F, et al. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 2002;52:20-33.
22. Bentley H, Hamdy FC, Hart KA, et al. Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1992;66:1159-63.
23. Yonou H, Aoyagi Y, Kanomata N, et al. Prostate-specific antigen induces osteoplastic changes by an autonomous mechanism. Biochem Biophys Res Commun 2001;289:1082-7.
24. Doherty A, Smith G, Banks L, Christmas T, Epstein RJ. Correlation of the osteoblastic phenotype with prostate-specific antigen expression in metastatic prostate cancer: implications for paracrine growth. J Pathol 1999;188:278-81.
25. Yi B, Williams PJ, Niewolna M, Wang Y, Yoneda T. Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 2002;62:917-23.
26. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944-9.
27. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998;19:18-54.
28. Goltzman D. Mechanisms of the development of osteoblastic metastases. Cancer 1997;80:1581-7.
29. Yang J, Fizazi K, Peleg S, et al. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res 2001;61:5652-9.
30. Lee Y, Schwarz E, Davies M, et al. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J Orthop Res 2003;21:62-72.
31. Lin DL, Tarnowski CP, Zhang J, et al. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001;47:212-21.
32. Yonou H, Yokose T, Kamijo T, et al. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res 2001;61:2177-82.
33. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000;18:1378-91.
34. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719-36.
35. Heidenreich A, Ohlmann C, Body JJ. Ibandronate in metastatic bone pain. Semin Oncol 2004;31:67-72.
36. Heidenreich A, Hofmann R, Engelmann UH. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 2001;165:136-40.
37. Parker CC. Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:1480-1.
38. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68.
39. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82.
40. Asahi H, Mizokami A, Maeda Y, Komatsu K, Koshida K, Namiki M. Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis. J Urol 2003;169:281-2.
41. Keller ET. Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 2004;91:718-29.
42. Keller ET. The role of osteoclastic activity in prostate cancer skeletal. Drugs Today (Barc) 2002;38:91-102.
43. Lee YP, Schwarz EM, Davies M, et al. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res 2002;62:5564-70.
44. Green JR. Bisphosphonates in cancer therapy. Curr Opin Oncol 2002;14:609-15.
45. Green JR, Clezardin P. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 2002;25:S3-9.
46. Corey E, Brown LG, Quinn JE, et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003;9:295-306.
47. Denoyelle C, Hong L, Vannier JP, Soria J, Soria C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer 2003;88:1631-40.
48. Saad F, Karakiewicz P, Perrotte P. The role of bisphosphonates in hormone-refractory prostate cancer. World J Urol 2005;23:14-8.
49. Oh JW, Drabik K, Kutsch O, Choi C, Tousson A, Benveniste EN. CXC chemokine receptor 4 expression and function in human astroglioma cells. J Immunol 2001;166:2695-704.